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A dysfibrinogenemia (fibrinogen Sevilla) was detected in a 64-yr-old woman with 
no previous history of hemorrhagic diathesis or thrombosis. Thrombin and reptilase 
times were prolonged. The aggregation of fibrin monomers showed a prolonged 
latency time with a defective slope although fibrinopeptide release and clot stabiliza- 
tion were found to be normal. Plasmin proteolysis was abnormal with a much 
slower plasmic degradation in patient’s purified fibrinogen. By chromatofocussing 
the patient’s fibrinogen showed an abnormality in pattern elution with a second 
peak eluting at a pH slightly more basic than the normal one @H 5.5). Likewise, the 
isoelectrofocussing of purified non-reduced patient’s fibrinogen in agarose gel 
showed an abnormal distribution in its focussed bands, especially in a group which 
focussed in a p&interval between 5.20-5.85. By two-dimensional electrophoresis we 
did not find any abnormality in the fibrinogen-reduced chains. These results could 
indicate that the abnormal monomer aggregation, as well as the defective plasmin 
lysis, could be due to conformational aspects of fibrinogen rather than to structural 
defects. 
Introduction 
The term dysfibrinogenemia describes the presence in plasma of an abnormal 
functional fibrinogen. Since the first description of a dysfibrinogenemia [l], the 
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number of reports of this abnormality have increased steadily [2]. In the majority of 
cases the basic molecular defect is unknown or has yet to be clearly established. 
Dysfibrinogenemias in which the molecular defect has been reported are associated 
with an aminoacid substitution which could affect any of the three chains [2]. 
In this study, we present a further variant of congenital dysfibrinogenemia which 
is characterized mainly by an anomalous monomer aggregation and a slower 
fibrinogen proteolysis by plasmin. 
Case report, materials and methods 
The propositus was a 64-yr-old Spanish female with no previous history of 
hemorrhagic diathesis of thrombosis. The dysfibrinogenemia was discovered by 
chance in a routine laboratory preoperative screening which showed a prolonged 
thrombin time. Analyses of family members revealed the same abnormality in a 
daughter and grandson. No member of her family had a history of hemorrhagic 
diathesis or thrombosis. 
The coagulation and fibrinolysis studies were as described elsewhere [3]. 
Fibrinogen purification was carried out as follows: BaSO, 100 mg/ml of plasma 
was added; the mixture was stirred for 1 h and centrifuged for 15 min. The 
supematant was submitted to double precipitation with glycine at a concentration 
of 165 mg/ml. The precipitate obtained was redissolved in the same volume of 
phosphate buffer 5 mmol/l, pH 7.4, containing epsilon aminocaproic acid (EACA) 
0.1 mol/l. The solution was submitted to double precipitation with (NH&SO, at 
26% saturation. The final precipitate was redissolved in the same phosphate, EACA 
buffer and dialyzed overnight against NaC10.3 mol/l. The coagulation index of the 
protein obtained ranged between 90-97%. Plasminogen contamination of the 
fibrinogen preparation could not be detected using the chromogenic substrate 
S-2251 (Kabi Diagnostica, Stockholm, Sweden) following the l-h incubation period. 
Coagulation of patient’s plasma was registered spectrophotometrically at 350 mn 
as described by Gruendlinger and Bouvier [4] using bovine thrombin (Diagnostic 
Reagents Ltd, Thame, Gxon, UK) (1 NIH/ml final concentration) and reptilase” 
(Pentapharm Ltd, Basle, Switzerland) (1 BU/ml) as inducing agents. 
We studied the influence of propositus plasma on normaI plasma thrombin time 
as described by Langen and Bithell [5], and the influence of Ca’+ ions on patient’s 
plasma thrombin time. 
Studies of fibrin formation 
Fibrinopeptide release was studied by HPLC * and its kinetics by a modification 
of the TCA method [5]. Fibrin monomer aggregation was measured by the tech- 
nique of Belitser et al. [6]. Fibrin stabilization was carried out according to Grahrick 
et al. [7] using patient’s plasma instead of purified fibrinogen solution, after having 
assessed normal levels of F. XIII. 
Fibrinogen proteolysis by plasmin was performed according to Denninger et al. 
[8]. Samples were studied by immunoelectrophoresis [9] and by SDSPAGE [lo] at 
different time intervals. 
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Physicochemical studies of purified fibrinogen 
Determination of the electrophoretic mobility of fibrinogen was performed in 
plasma and in purified fibrinogen by immunoelectrophoresis [9] and crossed im- 
munoelectrophoresis [ll] using two different batches of agarose (agarose A and C, 
Pharmacia Fine Chemicals) of different electroendosmosis. The mobility of the 
reduced forms of the three chains of normal and propositus fibrinogens was studied 
by SDS-PAGE (7.5%) [lo]. The sialic acid was measured by Aminoff’s thiobarbi- 
turic acid method [12] and the hexosamine content, by the technique of Cessi and 
Piliego [13]. The sedimentation coefficient was determined as described elsewhere 
[21* 
The heterogeneity of the purified fibrinogen for the patient was studied by three 
different techniques. 
1. By isoelectric focussing (IEF) of non-reduced purified fibrinogen which was 
performed in a Pharmacia horizontal apparatus in 1.6~mm horizontal slabs of 1% 
agarose (IEF grade, Pharmacia Fine Chemicals, Uppsala, Sweden) containing 12% 
(wt/vol) sorbitol, 5% (vol/vol) ampholines 3-10 pH range (Ampholine@, LKB 
Bromma, Sweden). A pre-electrophoresis was performed at 250 V, for 3-4 h after 
which 25 ~1 (20 pg) of the fibrinogen solution were applied near the cathode. 
Electrophoresis was continued overnight. Gels were fixed in 5% sulphosalicylic acid 
plus 10% trichloroacetic acid for 30 min, placed in a destaining solution of 
methanol:acetic acid&tilled water (3 : 1: 6) for 30 min and stained with Coomassie 
R-250 (Merck). The cathode solution used was NaOH 0.3 mol/l and the anode 
solution SO,H, 0.03 mol/l. A high pl calibration kit (Pharmacia Fine Chemicals, 
Uppsala, Sweden) was used as a control for the isoelectric points. 
2. By chromatofocussing in a diethyl-aminoethyl cellulose matrix (DE 52 What- 
man Ltd, Springfield Mill, UK) in columns of 0.9 X 25 cm. One ml of a fibrinogen 
solution (A 280 = 0.5) was applied to the column, previously balanced with buffer 
imidazol 0.025 mol/l, pH: 7.4. The chromatofocussing was run with polybuffer 74 
(Pharmacia) adjusted at pH: 4; flow rate was 25 ml/h and 3 ml fractions were 
collected. In each of these the pH (Model 4500 Digital pH meter, Beckman 
Instruments, Fullerton, CA, USA) and fibrinogen content were determined [14]. 
3. Two-dimensional polyacrylamide gel electrophoresis was carried out essentially 
as described by Polack et al. [15]. In the first dimension, ampholines 3.5-10 (LKB) 
were used in 4% acrylamide gels rods (0.25 X 7 cm) The second dimension was 
performed in homogeneous 10% acrylamide gels. 
Test of coagulation and fibrinolysis 
The results are shown in Table I. The activated partial thromboplastin time, 
thrombin and reptilase times together with fibrinogen concentrations determined by 
methods depending on the rate of coagulation, were abnormal. 
The spectrophotometric recording of coagulation in patient’s plasma showed a 
delay at the onset of clot formation with both reagents. With reptilase, the slope and 
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TABLE I 
Chgulation tests of patient 
Test 
Protrombin time (s) 
Activated partial tbrombopIastin time (s) 
Thrombin time (s) 
Reptilase time (s) 
Factors 11, V, VIII, IX, X, XX, XII, XIII (46) 
Plasma fibrinogen levels (mg/dl). 
Thrombin clotting time 
Tyrosine content 
Heat precipitation 
EleCvOimmtllloaSSay 
Single radial immmwdiffusion 
~tit~ornb~ III (mg/dl) 
Plasminogen (S) 
Euglobuliri lysis time (miu) 
Patient Normal 
12 12 
56 40 
38 18 
41 18 
Normal 80-130 
49 200-400 
123 200-400 
150 150-300 
280 200-400 
280 200-400 
33 30- 50 
110 70-130 
180 180 
final amplitude were similar to normal, whereas with thrombin, the slope was 
reduced and the final amplitude decreased (Fig. 1). 
The addition of abnormal plasma to normal plasma did not inhibit the latter’s 
thrombin time and the presence of calcium ions restored the abnormal plasma 
thrombin time (data not shown). 
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Fig. 1. Po&merization curves of the patient’s plasma (- - - - - -) and normal plasma ( -) after the 
addition of human tbrombin (1 NIHfml) and reptilase (1 BU/‘ml). 
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Fig. 2. HPLC profile of patient’s fibrinopcptides r&wed after prolonged thrombin action. The relation 
FpA: FpB - 0.84 is closest o 1, indicatiug no evidence of abnormal fibrinopeptides. AP, fibrinopeptide 
A phosphorylated; A, fibrinopeptide A; AY, Des-arg, fibrinopeptide A, B-R, Des-arg-fibrinopeptide B;
B, fibrinopeptide B. 
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Fig. 3. Fibrinopeptide release. A, Fibrinogen of propositus; 0, normal fibrinogen. Notice tbat the kinetics 
of fibrinopeptide release of patient’s fibrinogen was similar to normal. 
0.300 - 
0.240- 
0.160 - 
0.120- 
0.060- 
I- 
t 
11 11 11 0 II I II 1 I 
2 6 l0 14 16 22 26 30 
Time of incubatii hid 
Fig. 4. Polymerization of performed normal (- ) and patient (- - ----) fibrin monomers in 
phosphate buffer pH 7.4 at 25 o C. 
Studies of fibrin formation 
Release of fibrinopeptides after thrombin addition was similar for both normal 
and patient fibrinogem, either by the HPLC or the TCA me&xl (Figs. 2 and 3). 
Fig. 5. Immunoelcctrophonsis of sequential samples from plasmic digests. N, normal; P, propositus. 
Antisera in troughs is anti-human fibrinogen. 
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Fig. 6. SD~~ly~l~de gel electrophoresis of normal, non-reduced sequential samples from plasm& 
digest. 1, Katalase (mol wt 240000); 2, aldolasa (mol wt 158000); 3, albumin (mot wt 45000). 
Fig. 7. SDS-polyacrylamkk gel electrophoresis of patient, non ndua sequantial samples from plasmic 
digest. 1,2 and 3 are the same molecular weight markers pointed out in Fig. 4. 
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The aggregation of fibrin monomers showed a prolonged latency time with a 
defective slope, whereas the final v4ue was similar to normal (Fig. 4). Clot 
stabilization as judged by SDS-PAGE was found to be normal since both gamma 
dimers and alpha polymers were present (results not shown). 
Plasmin proteolysis of purified fibrinogen from the proposita was abnormal. The 
patient’s immunoelectrophoresis, unlike normal immunoelectrophoresis, showed the 
persistence of material cross reacting to fibrinogen antiserum at 24 h of proteolysis 
(Fig. 5). Whereas plasmic digest appear at early stages in normal purified fibrino- 
gen, SDS-PAGE showed this degradation to be slower in patient’s purified fibrino- 
gen (Figs. 6 and 7). 
By chromatofocussin g we were able to differentiate two different peaks in the 
elution of purified fibrinogen: the first of these, in which most of the fibrinogen was 
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Fig. 8. Cbromatofocussin g of normal and patient’s fibrinogen. Notice the difference in pH between the 
two second elution peaks. 
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present, eluted at a pH between 6.05-5.90; and the second peak which elutes a pH 
between 4.9-5.07. The patients fibrinogen shows an abnormality in pattern elution 
with its second peak eluting at a pH slightly more basic than normal‘(pH: 5.5) (Fig. 
8). 
Isoelectrofocussing in agarose gel 
The isolated purified fibrinogen presented a heterogeneity with the presence of 
various bands showing isoelectric points between p1 5.20-6.55. Although both the 
patient’s and normal fibrinogen were spread over the same interval of pZ, there were 
qualitative differences in both fibrinogens. Between these heterogenous bands, we 
can differentiate two groups, one of them focussing at ~15.20-5.85 and the other at 
pl 5.85-6.55. In the first group (more acid) we can observe in the patient’s 
fibrinogen a more cathodic band in comparison with the normal fibrinogen. In the 
second group (more basic) there is an almost complete absence of the extreme 
cathodic band in the patient’s fibrinogen (Fig. 9). 
Two dimensional electrophoresis of reduced fibrinogen revealed two main y and 
three B /3 chains and several weakly stained A a! chains (Fig. 10). The pattern was 
Fig. 9. Isoelectrofocussing in agarose gel of normal (N) and patient’s (P) fibrinogens. pZ, protein 
isoelectric point markers. (See test.) 
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Fig. 10. Twodimcmional ekctrophotis of reduce patient fibrinogen. (See text.) 
similar to that shown by the reduced normal fibrinogen and to that described by 
other authors [15,16]. 
Physicochemieal characteristics 
We found that the patient’s fibrinogen had sialic acid and hexosamine contents 
within normal limits, sin&r to normal fibrinogen. Its sedimentation coefficient was 
S 20.w = 8.20 (n: 8.20). The patient’s fibrinogen showed total antigenie community 
with the control. The electrophoretic mobility studied by SDS-PAGE in both 
reduced and non-reduced fibrinogen was normal and their were no differences in its 
mobility when studied by immunoelectrophoresis and crossed immunoelectrophore- 
sis (in both plasma and purified fibrinogen). 
Discussion 
The, results demonstrated the existence of an abnormal fibrinogen in a family 
with probable autosomal dominant inheritance. 
The spectrophotometric analysis of the coagulation of the patient’s plasma 
showed a delay when thrombin and reptikse were used as inducing agents, which 
agrees with the prolonged thrombin and reptilase times found in the coagulation 
studies of the plasma of the proposita. 
In six of the reported dysfibrinogenemias, an abnormal DEAE-chromatography 
is described [2]. In fibrinogens Bethesda III [17], Baltimore I [18], Paris II [19], 
Nancy [20] and Philadelphia [2], the abnormality lies in the elution of the first peak, 
whereas in Paris I [22], the two fibrinogen peaks emerged later than their presumed 
counterparts. 
Mosesson and Finlayson [23] have indicated that the differences in the elution 
characteristics of peaks 1 and 2 fibrinogen can be accounted for by the absence 
(peak 1) or the presence (peak 2) of a y-chain variant termed y’. 
By two-~~sion~ electrophoresis, we were nnabfe to find any abno~~ty in 
the r-chain of the patient’s fibrinogen. Nevertheless, the patient’s purified fibrino- 
gen showed an abnormal distribution in its focussed bands, especially in the group 
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which focus& on the pi interval of 5.2%%85. This ab~u~ty could explam the 
existence, in the experience of ~omatof ocussing of a peak which elutes at pII 55 
slightly more basic than the normal peak (PH 4.90). 
Our fibrinogen showed a delayed plasmin degradation with the persistence of 
high molecular weight components. Smilar abnormality is described in fibrinogens 
henna Eif f17f, Chapel Hill Xl1 [24j and Tolcyu f [25]. The first of these 
d~fib~~ene~as had clinical symptoms, and the latter two had an anodic 
mobility demonstrated by immunoelectrophoresis and decreased levels of plasma 
Factor XIIL The existence, in our case, of abnormal classes of fibrinogen, could be 
r~po~ible for an abnormal binding of plasmin to fibrmogen. 
On the other hand, the presence of these abnormal molecules of fib~~ogen could 
interact with the polymerization sites and could be responsible for both the delayed 
rate of clotting, especially when low concentrations of thrombin were used, and the 
abnormal polymerization of fibrin &onomers. 
We believe &at &is abnormal fib~og~ should be ~ta~vely donate 
“fibrinogen Sevilla” even though more extensive biochemical studies are needed to 
establish whether the fibrinogen present in this kindred is unique, 
The HPLC determination of fibrinopeptida release was kindly performed by Dr. 
David Lane at Charing Cross and Westminster Medical !School, University of 
London> London, UK. 
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